GlassScriptPhysician profile
Jeffrey Nudelman
NPI 1417936469
$1,093.82
in general payments reported to CMS, 2019-2025
13 companies · $85.47 in 2025
The $85.47 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $98.57 · 2021: $44.79 · 2022: $261 · 2023: $78.20 · 2024: $145 · 2025: $85.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $374.74 | 2019-2020 | |
| Abbvie INC. | $268.15 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $121.71 | 2019-2023 | |
| Biotissue Holdings INC. | $81.69 | 2019-2023 | |
| Alcon Vision LLC | $57.81 | 2025 | Tryptyr, Rocklatan |
| Oyster Point Pharma, INC. | $31.82 | 2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $30.09 | 2022 | |
| Dompe US, INC. | $27.66 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $23.90 | 2021 | |
| Shire North American Group INC | $23.74 | 2019 | |
| Harrow Eye, LLC | $21.04 | 2024 | Vevye |
| Glaukos Corporation | $16.29 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nudelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.